PALISADE BIO, INC.PALIEarnings & Financial Report
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm developing novel therapies for gastrointestinal and associated inflammatory disorders. Its lead product candidates address unmet medical needs including post-surgical intestinal complications and chronic digestive conditions, operating primarily in the U.S. healthcare market.
PALI Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
PALISADE BIO, INC. Q4 FY2025 Financial Summary
PALISADE BIO, INC. reported revenue of $0 for Q4 FY2025, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
PALISADE BIO, INC. Annual Revenue by Year
PALISADE BIO, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
PALISADE BIO, INC. Quarterly Revenue & Net Profit History
PALISADE BIO, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | N/A | N/A |
| Q3 FY2025 | $0 | — | $-2.9M | N/A |
| Q2 FY2025 | $0 | — | $-2.8M | N/A |
| Q1 FY2025 | $0 | — | $-2.2M | N/A |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $-3.5M | N/A |
| Q2 FY2024 | $0 | — | $-4.1M | N/A |
| Q1 FY2024 | $0 | — | $-3.5M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $12.7M | $12.9M | $9.3M | $10.9M | $8.2M | $6.7M | $7.0M | $134.3M |
| Liabilities | $2.6M | $2.9M | $2.7M | $3.4M | $2.9M | $4.0M | $3.8M | $5.0M |
| Equity | $10.1M | $9.9M | $6.6M | $7.5M | $5.3M | $2.6M | $3.2M | $129.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.2M | $-3.5M | $-3.1M | $-12.2M | $-2.3M | $-1.8M | $-3.6M | $-10.8M |